根据最新提交至美国证券交易委员会（SEC）的文件显示，生物制药公司ADC Therapeutics SA的部分持股股东可能在未来一段时间内，陆续出售其持有的公司普通股，总量最高可达9,834,776股。
此类由现有股东发起的二级市场发售，通常不会为公司带来新的融资。市场参与者将密切关注后续的实际出售情况，以评估其对股价的潜在影响。
根据最新提交至美国证券交易委员会（SEC）的文件显示，生物制药公司ADC Therapeutics SA的部分持股股东可能在未来一段时间内，陆续出售其持有的公司普通股，总量最高可达9,834,776股。
此类由现有股东发起的二级市场发售，通常不会为公司带来新的融资。市场参与者将密切关注后续的实际出售情况，以评估其对股价的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.